Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis.

It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth.

Pregnancy category AU: B1

Routes of administration-By mouth

Protein binding 82–90%

Metabolism- Liver (primarily CYP1A2)

Elimination half-life 10 hours

Excretion- Feces, urine

Deucravacitinib is indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).

Leave a Reply

Your email address will not be published. Required fields are marked *